34.57
price down icon5.75%   -2.11
after-market Dopo l'orario di chiusura: 34.84 0.27 +0.78%
loading

Perché le azioni Exelixis Inc (EXEL) sono in ribasso?

Abbiamo notato un calo di 5.75% nelle azioni di Exelixis Inc (EXEL) durante la sessione di negoziazione di 2025-04-04. Sebbene ciò possa essere attribuito alla normale volatilità o a vari fattori interni ed esterni, tieni presente che stiamo monitorando attivamente la situazione e forniremo aggiornamenti tempestivi il prima possibile!
2023-10-23:

Shares of Exelixis, Inc. (EXEL) dropped by 8.81% from $21.11 to $19.25 in the trading on Monday, October 23, 2023. The reason why EXEL stock down is due to the company's announcement on detailed results from its Phase 3 CABINET pivotal evaluating Cabozantinib in advanced neuroendocrine tumors:

  • The CABINET trial achieved its primary objective, showing significant improvements in median progression-free survival (PFS) for patients with advanced pancreatic neuroendocrine tumors (pNET) and extra-pancreatic NET (epNET).
  • The trial was halted early due to the remarkable efficacy observed during an interim analysis, with consistent safety profiles.
  • Exelixis plans to discuss these findings with the FDA to potentially offer a new treatment option for patients with these challenging cancers. Investors' cautious response to this news led to the decline in Exelixis, Inc.'s stock price.
$60.58
price down icon 3.01%
$69.18
price down icon 5.66%
$17.36
price down icon 8.20%
$31.11
price down icon 2.14%
$88.05
price down icon 4.30%
biotechnology ONC
$238.51
price down icon 9.76%
Capitalizzazione:     |  Volume (24 ore):